Advertisement.

CFRX Projected Dividend Yield

Com Par $ 0.0001/ContraFect Corp ( OTCBB : CFRX )

ContraFect is a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA), including lysins and amurin peptides, as new medical modalities for the treatment of antibiotic-resistant infections. Co.'s main DLA product candidate, exebacase, is being developed in patients with chronic prosthetic joint infections of the knee due to S. aureus or coagulase-negative Staphylococci. Co.'s other product candidate, CF-370, is designed to target gram-negative bacteria, including P. aeruginosa, K. pneumoniae and A. baumannii, and is effective in vivo activity against these pathogens, even against multidrug-resistant and extensively drug-resistant strains.

20 YEAR PERFORMANCE RESULTS

CFRX Dividend History Detail
CFRX Dividend News
CFRX Competitors News

# of Shares: 0

Closing Price: 0.00

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000